First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy

Cancer Discovery

Volumn 2, Issue 8, 2012, Pages 694-705

  Sen, Malabika ^a   Thomas, Sufi M ^a   Kim, Seungwon ^a   Yeh, Joanne I ^a   Ferris, Robert L ^a   Johnson, Jonas T ^a   Duvvuri, Umamaheswar ^a   Lee, Jessica ^a   Sahu, Nivedita ^a   Joyce, Sonali ^a   Freilino, Maria L ^a   Shi, Haibin ^a   Li, Changyou ^a   Ly, Danith ^b   Rapireddy, Srinivas ^b   Etter, Jonathan P ^c   Li, Pui Kai ^c   Wang, Lin ^a   Chiosea, Simion ^a   Seethala, Raja R ^a   Gooding, William E ^a   Chen, Xiaomin ^d   Kaminski, Naftali ^a   Pandit, Kusum ^a   Johnson, Daniel E ^a   Grandis, Jennifer R ^a   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; NSC 741763; OLIGONUCLEOTIDE; PROTEIN BCL XL; STAT3 DECOY; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENATURATION; DENSITOMETRY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; SURVIVAL; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84866254673     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0191     Document Type: Article

References (43)

1. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006;6:17-33.
2. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev 2004;4:97-105.
3. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11: 595-6.
4. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 2009;101:967-72.
5. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56.
6. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006;2006:pe30.
7. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 2008;7:78.
8. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 2010;10:117-26.
9. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199-210.
10. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997;94:3801-4.
11. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005;65:5828-34.
12. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999;18: 4657-68.
13. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006;6:231-41.
14. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011;17:3922-32.
15. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506.
16. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9.
17. Huang C, Yang G, Jiang T, Cao J, Huang KJ, Qiu ZJ. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J Gastroenterol 2011;17:2992-3001.
18. Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012;30:916-26.
19. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003;100:4138-43.
20. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;24:970-9.
21. Zhang X, Zhang J, Wang L, Wei H, Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149.
22. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
23. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8.
24. Shen J, Li R, Li G. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo 2009;23:237-43.
25. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009;63:983-95.
26. Becker S, Corthals GL, Aebersold R, Groner B, Muller CW. Expression of a tyrosine phosphorylated, DNA binding Stat3beta dimer in bacteria. FEBS Lett 1998;441:141-7.
27. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394:145-51.
28. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible methylation of promoter-bound STAT3 by histonemodifying enzymes. Proc Natl Acad Sci U S A 2010;107:21499-504.
29. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
30. Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson DM, Jr, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010;9:165.
31. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-8.
32. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-8.
33. Sands H, Gorey-Feret LJ, Ho SP, Bao Y, Cocuzza AJ, Chidester D, et al. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides. Mol Pharmacol 1995;47:636-46.
34. Uhlmann E, Peyman A, Ryte A, Schmidt A, Buddecke E. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol 2000;313:268-84.
35. Crinelli R, Bianchi M, Gentilini L, Palma L, Sorensen MD, Bryld T, et al. Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. Nucleic Acids Res 2004;32:1874-85.
36. Tomita N, Kashihara N, Morishita R. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol 2007;11:7-17.
37. Osako MK, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, Yuyama K, et al. Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3'-terminus. J Gene Med 2007;9:812-9.
38. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ, et al. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther 2004;11:916-23.
39. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009;27:1235-42.
40. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol 2008;21:1461-9.
41. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000;97:5633-8.
42. Murphy M, Jason-Moller L, Bruno J. Using Biacore to measure the binding kinetics of an antibody-antigen interaction. Curr Protoc Protein Sci 2006;Chapter 19:Unit 19.14.
43. Jason-Moller L, Murphy M, Bruno J. Overview of Biacore systems and their applications. Curr Protoc Protein Sci 2006;Chapter 19:Unit 19.13.